Endocrine Abstracts

The routine use of adjuvant RAI treatment in low-risk DTC remains controversial due to the lack of unequivocal evidences of its effectiveness in radically operated subjects. The aim of the study was a retrospective evaluation of long-term outcomes of combined DTC treatment to evaluate the impact of adjuvant RAI therapy in the low risk group. Primary hypothesis was: ‘if adjuvant RAI treatment was unnecessary, a delay in RAI administration would have no impact on long-term ...

Calcitonin and carcinoembryonal antigen are biochemical markers of medullary thyroid carcinoma (MTC). Assessment of the dynamics of their serum concentration allow for calculation of their doubling times that are independent risk factors for overall survival and progression-free survival in MTC. It is generally accepted that the dynamics and the doubling times remain stable during follow-up.Aim: The aim of the study was to retrospectively verify the stab...

Introduction: Reliable prognostic factors are crucial to choose the optimal treatment strategy and follow-up for differentiated thyroid carcinomas (DTC) patients. Thus, the aim of the study was a retrospective evaluation of prognostic factors of cancer relapse in patients treated in a single institution.Material: The study group consisted of 510 DTC patients, staged pT1b-T4N0-N1M0, treated with total thyroidectomy followed by complementary 131...

Papillary thyroid cancer (PTC) is well known family occurring cancer disease. It is estimated, that ~5% of differentiated thyroid cancers (where PTC is the most frequent) are hereditary. Susceptibility genes are poorly known, however, recently some SNPs located on chromosome 9 in FOXE1 locus (rs965513) and on chromosome 14 (rs944289) close to NKX2-1 locus have been confirmed to be associated with PTC in different populations.The aim of our study was to a...